Efficacy and safety of Micafungin in Febrile NeutropenicPatients Treated for Hematological Malignancies

Tomomi Toubai; Junji Tanaka; Shuichi Ota; Akio Shigematsu; Yusuke Shono; Makoto Ibata; Satoshi Hashino; Takeshi Kondo; Yasutaka Kakinoki; Nobuo Masauzi; Masaharu Kasai; Hiroshi Iwasaki; Mitsutoshi Kurosawa; Masahiro Asaka; Masahiro Imamura

doi:10.2169/internalmedicine.46.6021

ORIGINAL ARTICLES

Efficacy and safety of Micafungin in Febrile NeutropenicPatients Treated for Hematological Malignancies

Tomomi Toubai, Junji Tanaka, Shuichi Ota, Akio Shigematsu, Yusuke Shono, Makoto Ibata, Satoshi Hashino, Takeshi Kondo, Yasutaka Kakinoki, Nobuo Masauzi, Masaharu Kasai, Hiroshi Iwasaki, Mitsutoshi Kurosawa, Masahiro Asaka, Masahiro Imamura

Author information

Tomomi Toubai
Department of Hematology and Oncology, Hokkaido University Graduate School of Medicine
Junji Tanaka
Department of Hematology and Oncology, Hokkaido University Graduate School of Medicine
Shuichi Ota
Department of Gastroenterology and Hematology, Hokkaido University Graduate School of Medicine
Akio Shigematsu
Department of Hematology and Oncology, Hokkaido University Graduate School of Medicine
Yusuke Shono
Department of Hematology and Oncology, Hokkaido University Graduate School of Medicine
Makoto Ibata
Department of Hematology and Oncology, Hokkaido University Graduate School of Medicine
Satoshi Hashino
Department of Gastroenterology and Hematology, Hokkaido University Graduate School of Medicine
Takeshi Kondo
Department of Gastroenterology and Hematology, Hokkaido University Graduate School of Medicine
Yasutaka Kakinoki
Department of Internal Medicine, Asahikawa Kosei Hospital
Nobuo Masauzi
Department of Hematology, Hakodate City Hospital
Masaharu Kasai
Department of Hematology, Sapporo Hokuyu Hospital
Hiroshi Iwasaki
Department of Internal Medicine, Sapporo Kosei Hospital
Mitsutoshi Kurosawa
Department of Internal Medicine, Sapporo Kosei Hospital
Masahiro Asaka
Department of Gastroenterology and Hematology, Hokkaido University Graduate School of Medicine
Masahiro Imamura
Department of Hematology and Oncology, Hokkaido University Graduate School of Medicine

Keywords: febrile neutropenia, micafungin, fungal infection, empirical antifungal therapy, hematological malignancies

JOURNAL OPEN ACCESS

2007 Volume 46 Issue 1 Pages 3-9

DOI https://doi.org/10.2169/internalmedicine.46.6021

Details

Abstract

Objective: The purpose of this study was to prospectively evaluate the efficacy and safety of micafungin (MCFG) in empirical therapy for febrile neutropenic patients for whom antibiotic therapy was not effective for hematological malignancies.
Patients and Methods: Twenty-three hematological patients aged 27-82 years with febrile neutropenia for whom antibiotic therapy was not effective were enrolled in this study and responses to treatment were evaluated.
Results: Treatment success rate was 73.9%. Treatment success rates by primary diagnosis were 77.8% in patients with AML, 50.0% in patients with NHL and 87.5% in patients with other diseases. Moreover, MCFG at a dose of 100 mg or more have a tendency to be effective. One or more adverse events occurred in five (27.7%) of the patients during the study. All of these adverse events were below grade 2 toxicity.
Conclusions: Although the number of patients studied was limited, MCFG as a monotherapy seems to be effective and safe as an empirical therapy in patients with febrile neutropenia. However, further investigation using large-scale studies is needed. This study demonstrated the clinical efficacy and safety of MCFG in patients with febrile neutropenia and with hematological malignancies.

Corresponding author

Register with J-STAGE for free!